CareLink Connect - Technical Evaluation Study

NCT01989975 | Completed Results

• 1 other identifier: EUR06
• Study Type: observational
• Target: 40
• Locations: 2 countries
• Sites: 2

Brief Summary

The purpose of this study is to evaluate the performance, patient satisfaction and safety of connectivity gateway device CareLink Connect, transferring CGM (Continuous Glucose Monitoring) data from a VEO insulin pump to CareLink online (every 5th minute) and thereby making it available for patients or Care Partners individual web connected devices such as smartphones, tablets and PCs.

Conditions

Diabetes Mellitus

Keywords

Sensor-Augmented Pump Therapy; Connected Care

Outcome Measures

Primary Outcomes (2)

• CareLink Connect Activity: % of the Time Per Day When Cellular Connection Was Established

  The overall system connectivity between the pump, the CareLink Connect device, and the CareLink server will be measured. CareLink Connect activity will be measured by: * Date and time of CareLink Connect transmissions * Transmission type and data sent in CareLink Connect transmissions (includes RF messages and history uploads)

  Outcome measured after 15 days of use of the CareLink Connect Device

• Subject Experience After Using the Carelink Connect Device

  Subject experience after using the Carelink Connect device was evaluated with questionnaires. Subjects were asked the question: I felt that I had good control over my diabetes. Likert Scale of 1-7 was used in the study to evaluate the question (1 being the the worse, 4 being neutral and 7 being the best).

  Outcome measured after 15 days of use of the CareLink Connect Device

Secondary Outcomes (2)

• Number of Participants With Serious Adverse Events

  Outcome measured after 15 days of use of the CareLink Connect Device

• Number of Participants With Investigational Device Deficiencies

  Outcome measured after 15 days of use of the CareLink Connect Device

Eligibility Criteria

• Age: 12 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Clinic patients

You may qualify if:

• Subject between the age of 12 - 65 years that has a clinical diagnosis of insulin requiring diabetes for at least 1 year
• Subject is currently using a Paradigm® Veo™ Medtronic insulin pump for at least 3 months and willing to continue to use for the duration of the study.
• Subject has sufficient Continuous Glucose Monitoring use experience, as determined by the Investigator, and is willing to continuously use CGM for the duration of the study.
• Guidelines to evaluate the patients experience are:
• i. Subject has a minimum of 30 days of CGM use within a year prior to enrollment.
• ii. Subject has experience with and is able to, or has a Care Partner who can:
• Insert/change sensor,
• Recharge the transmitter.
• Read sensor data in real-time on the insulin pump screen.
• Subject is willing to, or has a Care Partner who can, perform at least the minimum required (2 per day) Blood Glucose readings to maintain CGM Sensor calibration.
• Subject, if under the age of 18, has a Care Partner who is willing to participate to the study, attend the study visit with the subject, and complete user's feedback questionnaires and Care Partner diary. Care Partners are optional for patients of 18 years of age or older.
• Subject and/or Care Partner have access to a computer with Internet access.
• Subject and/or Care Partner have access to an Internet connected device.
• Subject, or their legal guardian, is willing to allow a Care Partner to receive and view information transmitted by their Paradigm® Veo™ Medtronic insulin pump to a Mobile phone/Smartphone/tablet/PC via the CareLink Connect/CareLink Personal System.
• Subject is willing to keep CareLink Connect device in the same room as themselves or regularly carry the study device with them and maintain its operational status (at approximately 16h per 24h).

You may not qualify if:

• Female subject is pregnant, per urine pregnancy test performed at screening in women of child-bearing potential
• Female subject plans to become pregnant during the course of the study
• Subject is unable to tolerate tape adhesives of the infusion set and CGM sensor
• Subject has any unresolved adverse skin condition in the area of the pump infusion set or the CGM sensor placement (e.g. psoriasis, rash, Staphylococcus infection)
• The subject has known cellular connectivity problem at their home
• The subject is by the PI judged ineligible or unable to perform the study procedures jeopardizing the study results.

Sponsors & Collaborators

• Medtronic Diabetes: lead

Study Sites (2)

Steno Diabetes Center

Gentofte Municipality, 2820, Denmark

Location

Diabeter

Rotterdam, 3011, Netherlands

Location

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Results Point of Contact

• Title: Suiying Huang, Statistician
• Organization: Medtronic Minimed

suiying.huang@medtronic.com

8184763319

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 22, 2013
• First Posted: November 21, 2013
• Study Start: May 1, 2013
• Primary Completion: September 1, 2013
• Study Completion: September 1, 2013
• Last Updated: February 21, 2019
• Results First Posted: February 21, 2019

Record last verified: 2018-10

Locations

DK (1); NL (1)